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oes Kidney Function Alter the
enefit of Reperfusion Therapy
or ST-Segment Elevation
yocardial Infarction?*
eter B. Berger, MD, FACC,†
atricia J. M. Best, MD, FACC‡
anville, Pennsylvania; and Rochester, Minnesota
n the last decade, the importance of chronic kidney disease
CKD) as a cardiovascular risk factor has become clear. The
raded risk of CKD is present at all levels of renal function
nd is a risk factor in those with unrecognized cardiovascu-
ar disease or stable coronary disease or after a percutaneous
oronary intervention (PCI) or myocardial infarction (1,2).
n patients presenting with a myocardial infarction, mild
KD is associated with a 3-fold increase in mortality (1).
his risk increases progressively with declining renal func-
ion, to a maximum mortality risk in patients with end-stage
enal disease (ESRD) that is 15 times higher than in
atients with normal renal function. This finding has been
ubstantiated by similar findings in multiple studies, con-
rming that renal disease is a strong correlate of both early
nd late mortality (3–7).
See page 26
A frequent limitation of studies investigating the impact
f renal disease on post-infarction outcomes is that they
ften fail to differentiate acute renal failure from CKD.
ecause renal function before the infarction might not be
nown and because myocardial infarctions cause acute renal
ailure in some patients, studies often combine acute and
hronic kidney disease in such analyses, leading to an
verestimation of the impact of CKD on outcome. In acute
yocardial infarction, the development of acute renal failure
ore frequently occurs in higher-risk patients, such as those
ith reduced left ventricular function, higher Killip class,
nterior wall infarction, a hematocrit 30%, congestive
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
From the †Department of Cardiology and Center for Clinical Studies, Geisingert
linic, Danville, Pennsylvania; and the ‡Division of Cardiovascular Diseases, Mayo
linic, Rochester, Minnesota.eart failure, shock, and stroke during hospital stay (8). In 1
tudy, the presence of acute renal failure was independently
ssociated with both short-term and long-term mortality
hazard ratio [HR] at 10 years: 1.15 for mild, 1.23 for
oderate, and 1.33 for severe acute renal failure). In other
tudies, both acute renal failure and the degree of change in
reatinine correlated with both the eventual development of
SRD and with mortality (9). Thus, in acute myocardial
nfarction, both acute renal failure and CKD are strongly
orrelated with adverse events including death.
Because CKD patients with an acute myocardial infarc-
ion have such a high mortality, treatment of the myocardial
nfarction is even more important than in patients with
ormal renal function. Reperfusion therapy has been a
undamental component of therapy for ST-segment eleva-
ion myocardial infarctions (STEMIs) since the 1980s,
hen landmark trials such as ISIS-2 (Second International
tudy of Infarct Survival) and GISSI-1 (Gruppo Italiano
er lo Studio della Sopravvivenza nell’Infarto) demonstrated
he ability of fibrinolytic therapy to reduce mortality (10–
2). Subsequent studies in the 1990s confirmed the ability
f primary PCI to reduce mortality more than fibrinolytic
herapy and to reduce re-infarction and stroke to an even
reater degree (13,14). Despite the proven effectiveness of
eperfusion therapy in the general population, significantly
ess is known about reperfusion therapy in patients with
KD or ESRD, because these patients have generally been
xcluded from randomized trials.
Given the high-risk population of patients with CKD
nd ESRD, it is surprising that reperfusion therapy is so
everely underused. Patients with ESRD are only a one-
uarter as likely to undergo reperfusion therapy as patients
ith normal renal function (1). Underuse of reperfusion
herapy is present with all levels of renal dysfunction. Even
n patients with mild CKD, reperfusion therapy is admin-
stered 30% less frequently. Patients with CKD or ESRD
ndergo coronary angiography 30% less frequently than
hose with normal renal function and are revascularized only
ne-half as often (15).
Despite the potential benefits, patients with CKD have a
igher complication rate from reperfusion therapy, includ-
ng bleeding, stroke, infarct-artery re-occlusion, and reste-
osis (3). In ESRD treated with dialysis, the mortality of a
yocardial infarction has been reported to be as high as 59%
t 1 year (16). So regardless of the fact that there are more
requent complications from reperfusion therapy, after ad-
usting for comorbidities, fibrinolytic therapy is associated
ith a 28% reduction in all-cause mortality in ESRD
atients (17). In another study of 5,549 patients with acute
yocardial infarction stratified by renal function that in-
luded 4,119 patients with at least mild CKD, there was an
1% reduction in mortality with fibrinolytic therapy and a
5% reduction in mortality associated with cardiac cathe-
erization (5). As with patients without CKD, patients with
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35KD would be expected to derive greater benefit from
rimary PCI than from fibrinolytic drugs and might have
ven relatively greater benefit, given the higher mortality
isk and the greater bleeding risk in CKD patients treated
ith fibrinolytic therapy. Before the current study by Medi
t al. (18) in this issue of JACC: Cardiovascular Interventions,
of the few studies to address this was a study from the
002 ACSIS (Acute Coronary Syndrome Israeli Survey),
hich included only 132 patients with CKD (19). In that
mall study, there was a trend toward a higher, not lower,
ortality risk at 7 days with primary PCI compared with
brinolytic therapy (HR: 3.8; 95% confidence interval: 0.9
o 26.7) and 30 days (HR: 7.3; 95% confidence interval: 1.8
o 50.4). In another nonrandomized study of 4,758 patients
ith acute coronary syndromes including 36% STEMI
nalyzed by renal function where 3,592 had at least mild
KD, they found a long-term mortality reduction in those
ith CKD treated with PCI (20). This mortality reduction
as greater than that seen with coronary artery bypass
urgery.
The study by Medi et al. (18) is now the largest to
valuate reperfusion strategy in patients with an acute
TEMI in which a detailed analysis of renal function was
ncluded. In this post hoc analysis of the prospective
RACE (Global Registry of Acute Coronary Events),
2,532 STEMI patients were evaluated, of whom 3,450 had
t least moderate CKD. The investigators reported that
atients with greater degrees of CKD were less likely to
eceive reperfusion therapy, as had been reported in many
maller studies. They found that 3.7% of patients with
ormal renal function or mild CKD did not receive reper-
usion therapy, which rose to 15.1% with moderate CKD,
nd 31.5% with severe CKD. However, the principle and
ew finding was that primary PCI was associated with a
ower adjusted in-hospital mortality compared with fibrino-
ytic therapy in the normal renal function group (odds ratio:
.51) and in those with moderate CKD (odds ratio: 0.66).
n the severe CKD group the odds ratio was 0.72, but this
ailed to reach statistical significance. As has been reported
n many other studies, primary PCI was also associated with
lower risk of stroke, which remained true at all levels of
enal function. Despite this finding primary PCI was not
ssociated with a statistically significant benefit compared
ith no therapy in those with CKD. At 6 months, in
atients with normal renal function and in those with
oderate CKD, there was a significant reduction in mor-
ality associated with primary PCI compared with no
eperfusion therapy. In patients with severe CKD, the
ortality at 6 months was increased with either PCI or
brinolytic therapy compared with no reperfusion therapy.
hus, this study exemplified the complexity of reperfusion
herapy and the limited knowledge in patients with CKD.
his study suggests that patients with moderate, but notevere, CKD might benefit from primary PCI in an acuteTEMI. Additionally, this study demonstrates less risk of
omplications of stroke with primary PCI in patients with
oderate or severe CKD when compared with fibrinolytic
herapy.
In-hospital and long-term therapy with aspirin, beta
locker drugs, statin drugs, and angiotensin-converting
nzyme inhibitor drugs is an essential part of the treatment
or myocardial infarction. Such therapy is under-prescribed
y up to 50% in CKD patients (4,5,21-23). Despite a
aucity of prospective randomized trials that included pa-
ients with CKD after a myocardial infarction, retrospective
ata suggest that CKD patients derive a similar benefit from
spirin, beta blocker drugs, and statin drugs as patients
ithout CKD (21,24). They might receive even greater
enefit from angiotensin converting enzyme inhibitor drugs
25). Unfortunately, as with reperfusion therapy, patients
ith the greatest renal dysfunction and highest mortality after
yocardial infarction are prescribed the least medical therapy.
Patients with CKD at all levels are at increased risk of
ying from myocardial infarction. Aggressive therapy is
arranted. When choosing reperfusion, primary PCI might
ave greater benefit in patients with moderate CKD com-
ared with fibrinolytic therapy, with lower risk of stroke.
owever, in those with severe CKD this study did not
stablish an optimal reperfusion strategy. Medi et al. (18)
re to be congratulated for performing the largest study to
ate to address the most appropriate method of reperfusion
herapy for CKD patients, which has added to our under-
tanding of appropriate reperfusion therapy in CKD. How-
ver, further studies will be necessary to fully understand the
ole of each revascularization therapy in the high-risk
atient with CKD.
eprint requests and correspondence: Dr. Patricia J. M. Best,
ivision of Cardiovascular Diseases, Mayo Clinic, Gonda 5, 200 First
treet SW, Rochester, Minnesota 55905. E-mail: best.patricia@
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